New Version of TCS’ MRT Platform to Help Pharma Cos Digitally Transform Clinical Studies

Tata Consultancy Services’ Platform, Part of its Advanced Drug Development Suite, to Automate Clinical Study Set Up and Data Analysis to Accelerate Launch of New Products and Deliver Business Agility

FRANKFURT | MUMBAI, March 11, 2019: Tata Consultancy Services (TCS), (BSE: 532540, NSE: TCS) a leading global IT services, consulting and business solutions organization, has launched a new version of the Metadata Registry and Transformation (MRT) Platform that helps life sciences companies streamline their clinical data management by automating clinical study design and set up and conversion of clinical data into standard formats for greater interoperability across the clinical trial phases.

The MRT platform is part of TCS’ Advanced Drug Development (ADD) suite of cloud-based clinical platforms, which are powered by a cognitive engine. The latest version comes with a modernized automation engine and offers significantly enhanced capabilities across both its modules:

Clinical Metadata Registry: Helps create and manage a metadata library to accelerate clinical study set-ups and consumption across various study phases. The metadata backbone across clinical trial phases ensures a seamless exchange of information across phases within and outside the company. This enables a seamless cascade of changes in metadata vertically and horizontally across clinical trials.

Clinical Data Transformation: Powered by TCS’ unique code generation engine, the component automates the conversion of clinical data to Clinical Data Interchange Standards Consortium (CDISC) or sponsor-specific standards.

TCS has successfully implemented the platform at a leading pharmaceutical company, Boehringer Ingelheim, helping it revolutionize its clinical development process. Andrea Rauch, Head, Clinical Data Standards and Business Capabilities, Boehringer Ingelheim, said, “With the successful roll-out of MRT, we are able to maintain and govern our company, therapeutic area, and project standards using configurable workflows while pushing our study metadata to our EDC system with the click of a button. This is a first step and further releases will offer us an opportunity to revolutionize our clinical development by automating the process of converting study data to submission-ready SDTM data. This implementation is part of Boehringer Ingelheim’s Biometrics and Data Sciences Strategy to set-up and conduct clinical studies and analyze data while supporting our mission of bridging data to solutions.”

“Our MRT platform, inspired by TCS’ Machine First™ Delivery Model, brings automation to clinical trials and helps life sciences companies accelerate drug launches, achieve better regulatory compliance, and gain business agility,” said Debashis Ghosh, President, Life Sciences and Healthcare, TCS. “With our deep knowledge of the life sciences industry, we are continually expanding the capabilities of ADD, our advanced cloud-based suite, to help our customers digitally transform the different elements of their drug development value chain. We are excited to have Boehringer Ingelheim as a key customer on the latest release of the platform.”

About TCS Advanced Drug Development (ADD) Suite:

TCS’ Advanced Drug Development (ADD) suite offers a wide range of Cloud-based clinical services, including Clinical Data Management, Metadata Management, Pharmacovigilance, and Data Analytics and Insights. ADD is powered by a cognitive engine called ‘Decision Fabric’ that enables automation of complex business processes. ADD leverages the best of Cloud architecture and intuitive user experience design in compliance with “Good Clinical Practice” quality guidelines and privacy regulations.

About TCS Life Sciences:

TCS Life Sciences provides top global Life Sciences organizations full service offerings in IT, Consulting, KPO, Infrastructure, and Engineering Services, as well as digital solutions using Mobility, Big Data, Analytics, and Cloud. TCS’ rich industry experience, domain expertise and global footprint allows for a seamless partnership with its Life Sciences customers to help them advance clinical trial efficiencies, accelerate drug discovery, accentuate manufacturing productivity, and amplify sales and marketing effectiveness. In addition, TCS has a dedicated Life Sciences Innovation Lab, which ensures that its customers have the tools and innovative solutions they need to solve complex business challenges.

About Tata Consultancy Services Ltd. (TCS)

Tata Consultancy Services is an IT services, consulting and business solutions organization that has been partnering with many of the world’s largest businesses in their transformation journeys for the last fifty years. TCS offers a consulting-led, cognitive powered, integrated portfolio of business, technology and engineering services and solutions. This is delivered through its unique Location Independent Agile delivery model, recognized as a benchmark of excellence in software development.

A part of the Tata group, India's largest multinational business group, TCS has over 417,000 of the world’s best-trained consultants in 46 countries. The company generated consolidated revenues of US $19.09 billion in the fiscal year ended March 31, 2018, and is listed on the BSE (formerly Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. TCS' proactive stance on climate change and award winning work with communities across the world have earned it a place in leading sustainability indices such as the Dow Jones Sustainability Index (DJSI), MSCI Global Sustainability Index and the FTSE4Good Emerging Index. For more information, visit us at www.tcs.com.

To stay up-to-date on TCS news in North America, follow @TCS_NA. For TCS global news, follow @TCS_News.